ArticleJournal of gastroenterology2026
Cytotoxic immune activity reflects a coordinated immune microenvironment and is associated with response to total neoadjuvant therapy in rectal cancer.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundTotal neoadjuvant therapy (TNT) has emerged as a promising treatment strategy for locally advanced rectal cancer; however, robust biomarkers predicting treatment response remain lacking. We aimed to identify pretreatment transcriptomic determinants of TNT response, focusing on cytotoxic immune activity and its broader immune context.
methodsWe analyzed two independent cohorts of patients with rectal cancer treated with TNT: a laser-capture microdissection (LCM) cohort (n = 154) and a bulk tumor cohort (n = 80). Differential gene expression, gene set enrichment, and immune deconvolution analyses were performed using pretreatment RNA sequencing data. Associations between cytotoxic activity and treatment response were evaluated using multivariable models.
resultsOnly a limited number of genes were reproducibly associated with response across cohorts. Pathway-level analyses revealed enrichment of immune-related signatures in complete responders in the bulk cohort, whereas no significant enrichment was observed in the LCM cohort. Cytotoxic scores showed a consistent directional association with complete response in both cohorts, although modestly, and did not reach statistical significance in the LCM cohort. Cytotoxic activity was strongly correlated with multiple immune cell populations and signaling pathways, including effector and regulatory components, indicating a coordinated immune microenvironment. Multivariable analyses demonstrated that cytotoxic activity was independently associated with treatment response in the bulk cohort and recurrence-free survival in the LCM cohort.
conclusionsCytotoxic immune activity represents a biologically relevant but modest determinant of response to TNT in rectal cancer. These findings suggest that treatment sensitivity is shaped by a coordinated immune microenvironment rather than cytotoxic activity alone.
Indexed as
Identifiers
42611325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.